FLICE Induced Apoptosis in a Cell-free System
CLEAVAGE OF CASPASE ZYMOGENS*

(Received for publication, November 11, 1996)

Marta Muzio Dagger §, Guy S. Salvesen and Vishva M. Dixit Dagger par

From the Dagger  Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109 and the  Burnham Institute, San Diego, California 92037

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

Engagement of CD95 or tumor necrosis factor 1 receptor (TNFR-1) by ligand or agonist antibodies is capable of activating the cell death program, the effector arm of which is composed of mammalian interleukin-1beta converting enzyme (ICE)-like cysteine proteases (designated caspases) that are related to the Caenorhabditis elegans death gene, CED-3. Caspases, unlike other mammalian cysteine proteases, cleave their substrates following aspartate residues. Furthermore, proteases belonging to this family exist as zymogens that in turn require cleavage at internal aspartate residues to generate the two-subunit active enzyme. As such, family members are capable of activating each other. Remarkably, both CD95 and TNFR-1 death receptors initiate apoptosis by recruiting a novel ICE/CED-3 family member, designated FLICE/MACH, to the receptor signaling complex. Therefore, FLICE/MACH represents the apical triggering protease in the cascade. Consistent with this, recombinant FLICE was found capable of proteolytically activating downstream caspases. Furthermore, CrmA, a pox virus-encoded serpin that inhibits Fas and tumor necrosis factor-induced cell death attenuates the ability of FLICE to activate downstream caspases.


INTRODUCTION

Apoptosis, or programmed cell death, is a cell deletion mechanism that is critical to metazoan survival (1, 2). The cell death machinery is conserved throughout evolution and is composed of several distinct parts including effectors, inhibitors, and activators (2, 3).

It is becoming apparent that mammalian cysteine proteases (designated caspases)1 related to the Caenorhabditis elegans cell death gene CED-3 represent the effector components of the apoptotic machinery. The first mammalian homolog of CED-3 to be identified was interleukin-1beta converting enzyme (ICE) (4). Further studies, however, suggested that proteases related to ICE, rather than ICE itself, may play a more central role in the apoptotic mechanism. To date, 10 homologs of CED-3 and ICE (caspase-1) have been characterized and include Nedd-2/ICH1 (caspase-2) (5, 6), Yama/CPP32/apopain (caspase-3) (7-9), Tx/ICH2/ICE rel-II (caspase-4) (10-12), ICE rel-III, (caspase-5) (12), Mch2 (caspase-6) (13), ICE-LAP3/Mch3/CMH-1 (caspase-7) (14-16), ICE-LAP6 (caspase-9) (17), Mch4/FLICE2 (caspase-10) (18),2 ICH3 (caspase-11) (20), and FLICE/MACH (caspase-8) (21, 22). Ectopic expression of these ICE/CED-3 homologs in a variety of cells induces apoptosis. However, only Yama, LAP3, and Mch2 have been shown to be proteolytically activated by apoptotic stimuli including engagement of the CD95 and TNFR-1 receptors (14, 23, 24). Both these receptors utilize the adaptor molecule FADD as a conduit to relay death signals into the cells' interior. Indeed, a discrete domain within FADD, designated the death effector domain, was found capable of engaging the cells death machinery and inducing apoptosis (25-27). The surprising revelation was the finding that the death effector domain of FADD bound to corresponding sequence motifs within the prodomain of FLICE/MACH and thereby recruited this putative death protease to the receptor signaling complex (21, 22). This suggested that FLICE was the apical triggering protease and should be competent to initiate proteolytic activation of downstream caspase family members resulting in apoptotic demise. The pox virus-encoded serpin cytokine response modifier A gene (CrmA) binds with differential affinity to the active forms of ICE and ICE-like proteases (8) and blocks cell death triggered by either death receptor (28-30). Normally, engagement of these receptors results in prompt proteolytic activation of the downstream caspases including Yama, LAP3, and Mch2. In CrmA-expressing cells, Yama, LAP3, and Mch2 remain as proenzymes, suggesting that CrmA likely inhibits an upstream ICE-like protease such as FLICE (14, 23, 24).

In this study, the apoptotic potential and substrate specificity of recombinant FLICE was determined in a cell-free system. Additionally, FLICE was examined as a potential CrmA target.


MATERIALS AND METHODS

Expression of Recombinant FLICE

The ICE homology region of FLICE (encoding Ser-217 to Asp-479) was polymerase chain reaction-amplified and subcloned into the bacterial expression vector pET15b (Novagen). Oligonucleotides used for amplification were as follows. Upstream, CAAGAGAACATATGAGTGAATCACAGACTTTGGACAAAG; downstream, CAGGGATCCTCAATCAGAAGGGAAGACAAGTTT.

The protein was expressed in the BL21 pLysS Escherichia coli strain and purified using the QIAexpress Kit (Qiagen) following the manufacturer's instructions.

35S-Labeled Substrates

cDNA encoding human ICE, ICH-1L, Tx, ICE-LAP3, ICE-LAP6, FLICE, FLICE2, Mch2, Yama, CrmA, and proIL-1beta were subcloned into the mammalian expression vector pcDNA3 (Invitrogen) that is driven in vitro by the T7 promoter. Plasmid templates were used in coupled in vitro transcription/translation reactions to generate [35S]methionine-labeled proteins (Promega).

Protease Assay

Cytosolic extracts were prepared from untreated (naive), CD95-stimulated Jurkat cells, or LPS (100 ng/ml)-treated THP-1 cells, as described previously (31). Nuclei were prepared from HeLa cells also as described previously (32). In vitro apoptotic reactions were assayed by the addition of 106 HeLa nuclei to 40 µl of extract (6 mg/ml protein concentration), in the presence or absence of recombinant FLICE. In instances where tetrapeptide inhibitors (Bachem) were used, they were added to naive extract 10 min prior to the addition of FLICE. Agarose gel analysis for DNA fragmentation was performed as described previously (31). Immunoblotting of extracts for the large catalytic subunit of LAP3 and Yama and for diagnostic PARP and lamin A cleavage products was carried out as described previously (33). A careful titration was performed to determine the lowest concentration of FLICE sufficient to induce DNA fragmentation and this was then used in all subsequent experiments unless otherwise noted.

In Vitro Binding Assay

50 ng of recombinant FLICE in the presence or absence of 20 µM Ac-DEVD-CHO tetrapeptide inhibitor was incubated with 35S-labeled CrmA in a total volume of 100 µl of buffer (50 mM HEPES, 0.5% CHAPS, 150 mM NaCl, 0.005% bovine serum albumin); an aliquot of each reaction (10 µl) was resolved by SDS-PAGE and subjected to autoradiography to confirm the presence of CrmA. The remaining sample was diluted to 1 ml in binding buffer (0.1% Nonidet P-40, 400 mM NaCl, 0.005% bovine serum albumin, 1 mM EDTA, 50 mM HEPES) and immunoprecipitated with a rabbit polyclonal FLICE (small subunit) antiserum. Precipitates were resolved by SDS-PAGE and analyzed by autoradiography to detect associating CrmA.

Transfection and Immunoprecipitation Analysis

FLICE cDNA epitope-tagged (HA) at the C terminus was co-transfected with a CrmA expression construct into 293 cells. After 48 h, cells (5 × 106) were lysed in 1 ml of binding buffer, an aliquot (50 µl) was resolved by SDS-PAGE, and the presence of CrmA was confirmed by immunoblotting. The remaining lysate was immunoprecipitated with a monoclonal HA-epitope tag antibody, and the immune complex was resolved by SDS-PAGE and analyzed by immunoblotting to detect coprecipitating CrmA.


RESULTS AND DISCUSSION

FLICE Induces Apoptosis in a Cell-free System

A cell free system was utilized to investigate if recombinant FLICE could proteolytically activate caspase zymogens implicated in apoptosis. In most cell types, fragmentation of nuclear DNA into internucleosomal size fragments is the biochemical hallmark of apoptosis. Recombinant FLICE did not induce DNA fragmentation when added directly to indicator HeLa nuclei, suggesting that by itself it was incapable of inducing apoptosis (Fig. 1A). However, in the presence of a cytosolic extract from untreated Jurkat cells (naive extract), it was competent to trigger DNA fragmentation (Fig. 1A). Therefore, essential cytosolic cofactors were required for FLICE to drive the apoptotic reactions to completion. Several independent studies have reported that caspase family members rapidly cleave PARP and lamin A during apoptosis to signature 85- and 40-kDa fragments, respectively (9, 24, 34). Consistent with these studies, FLICE in the presence of naive extract induced cleavage of PARP and lamin A to characteristic apoptotic fragments (data not shown).


Fig. 1. Recombinant FLICE induces apoptosis in a cell-free system. A, HeLa nuclei were incubated with naive extract for 2 h at 30 °C (lane 1). Recombinant purified active FLICE (50 ng) was incubated with HeLa nuclei in the presence (lane 3) or absence (lane 2) of naive extract, and DNA fragmentation was analyzed by agarose gel electrophoresis. B, HeLa nuclei were incubated with naive extract and FLICE (lane 1) for 2 h at 30 °C. Decreasing concentrations of Ac-DEVD-CHO (lanes 2-5) or Ac-YVAD-CHO (lanes 6-9) were added to naive extract prior to FLICE incubation. DNA fragmentation was analyzed as above.
[View Larger Version of this Image (42K GIF file)]


Two different tetrapeptide aldehydes based on the cleavage sequence in PARP (Ac-DEVD-CHO) and IL-1beta (Ac-YVAD-CHO) irreversibly inhibit select members of the caspase family (8, 35). At nanomolar concentration ranges, Ac-DEVD-CHO attenuates Fas and Yama-induced apoptosis and inhibits Yama-mediated PARP cleavage, whereas Ac-YVAD-CHO inhibits only ICE-mediated IL-1beta cleavage (36-38). However, at higher concentrations, Ac-YVAD-CHO will also attenuate ICE- and Fas-induced cell death (28, 38). Both inhibitors were added to naive extracts, and the ability of FLICE to trigger DNA fragmentation was analyzed. As shown in Fig. 1B, Ac-DEVD-CHO potently inhibited FLICE-induced apoptosis whereas Ac-YVAD-CHO was effective only at higher concentrations, suggesting preference for the DEVD inhibitor. This inhibitor could either be blocking FLICE directly or, alternatively, a downstream caspase family member such as Yama that is susceptible to inhibition by Ac-DEVD-CHO.

FLICE Cleaves Various Members of the Caspase Family of Cysteine Proteases

Activation of caspase family members is tightly regulated and occurs by the proteolytic processing of a single polypeptide-inactive zymogen to an active dimeric species consisting of large and small subunits. All caspases cleave their known substrates following an Asp residue. Indeed, caspase zymogens are themselves activated by cleavage at internal Asp residues that conform to the substrate consensus for the protease family. Not surprisingly, therefore, caspase family members are capable of activating each other, and members have been shown to self-activate when overexpressed in bacteria. It thus appears reasonable to postulate that a cascade of activation occurs in cells upon triggering of the apical death protease. Given this, the activation of nine caspase zymogens was monitored by detecting the emergence of the two-chain active enzyme in cytosolic extracts exposed to recombinant FLICE.

To analyze processing of caspase family members for which antibodies were not available, an assay was developed to monitor processing of radiolabeled zymogen. The validity of such an approach was confirmed by monitoring in parallel the processing of endogenous zymogen and exogenously added radio-zymogen. Tracer amounts of radiolabeled Yama and LAP3 were added to naive extract and processing of endogenous molecules was assessed by immunoblotting and that of exogenous radiolabeled zymogens by autoradiography. As shown in Fig. 2A, identical cleavage products were detected by either method, confirming the validity of using radiolabeled zymogen in instances where antibody reagents are not available. Of note was the exceptional sensitivity of the radiotracer method. Additionally, it was possible to monitor the emergence of both the large and small radiolabeled subunits upon processing. The immunoblotting detection technique was restricted to one or other subunit depending upon the specificity of the antibody reagent.


Fig. 2. Differential activation of ICE-CED3 family members following addition of FLICE to naive extracts. A, activation of Yama (left panels) and LAP3 (right panels) in naive extract incubated with recombinant FLICE for 2 h at 30 °C. The zymogen form of Yama and LAP3 is evident in naive extract in the absence of FLICE (lane 1). The presence of the large catalytic subunit of Yama and LAP3 as detected by immunoblotting or large and small catalytic subunits detected by autoradiography is indicative of activation and is observed following incubation of naive extract with increasing concentrations of recombinant FLICE (lanes 2-4 for Yama and lane 2 for LAP3). B, radiotracer analysis of the activation of Tx, ICH1, LAP3, LAP6, FLICE2, ICE, Yama, and Mch2 pro-enzymes (lanes 1, 4, 7, and 10) in the presence (lanes 3, 6, 9, and 12) or absence (lanes 2, 5, 8, and 11) of naive extract incubated with recombinant FLICE for 2 h at 30 °C. C, time course analysis of the activation of Yama, LAP3, Mch2, Tx, LAP6, and ICH1 radio-zymogens (lane 1) in the presence of naive extracts incubated with recombinant FLICE for the indicated periods of time (lanes 2-6).
[View Larger Version of this Image (51K GIF file)]


As shown in Fig. 2B, FLICE directly cleaved Yama, LAP3, Tx, LAP6, and FLICE2 in the absence of naive extract; in contrast, Mch2 and ICH1 were efficiently cleaved only in the presence of naive extract. An identical pattern of cleavage products was observed in the presence of apoptotic extracts from CD95 stimulated cells (Ref. 33 and data not shown). Taken together, these results are consistent with the requirement of an intermediary cytosolic component for FLICE-mediated activation of Mch2 and ICH1. The other family members, however, can be directly processed by FLICE. Intriguingly, ICE was not a substrate for FLICE even in the presence of cytosolic extract and was not cleaved by apoptotic extracts from CD95 stimulated cells (data not shown). This was surprising as ICE or a very similar protease has been proposed to be an important component of the CD95 death pathway (39). Prior studies had shown a sequential activation of ICE-like and CPP32-like proteases to occur during this process (38). The ICE zymogen used in the studies was not defective as it was appropriately proteolytically processed by extracts from LPS-stimulated THP-1 cells, a rich source of enzymatically active ICE (data not shown). Taken together, the data suggest that ICE does not participate in FLICE-mediated apoptosis. Consistent with this finding is the recent report that fails to observe processing of pro-ICE during CD95-induced apoptosis (40). A time course study was undertaken to determine the rapidity of processing of the other family members by FLICE in the presence of naive extract. As shown in Fig. 2C, prior to treatment with recombinant FLICE, only the zymogen form of the respective proteases was detectable. However, within 5 min of exposure to FLICE, cleavage products for Yama and Tx were evident. LAP3 and LAP6 processing followed soon thereafter, being visible by 15 min. Only at a relatively late stage (1-2 h) was processing of Mch2 and ICH1 observed, supporting the initial conclusion that their activation was not directly mediated by FLICE but rather required an intermediary step (Fig. 2C).

Collectively, these data demonstrate that FLICE is capable of triggering the processing of downstream death proteases, consistent with its being the most apical member of the cascade.

FLICE, a Potential CrmA Target

CrmA is a potent inhibitor of serum withdrawl, TNF- and CD95-induced apoptosis (28, 30, 41), and IL-1beta release (42). The inhibition of IL-1beta release is almost certainly the result of CrmA inhibition of ICE. This abrogates proteolytic maturation of the cytokine, leading to its intracellular retention. The CrmA target responsible for inhibition of apoptosis has been less clearly defined. We previously showed that the CrmA target for apoptosis inhibition was proximal to the downstream effector proteases Yama, LAP3, and Mch2 (23, 24), thereby raising the possibility that an upstream protease such as FLICE was the CrmA target. In keeping with this notion, recombinant CrmA blocked FLICE-induced DNA fragmentation of indicator HeLa nuclei in a cell-free system (Fig. 3A). Since it had previously been shown that 15 ng of recombinant CrmA completely blocked the activity of 0.5 ng of recombinant ICE (42), we asked whether a similar ratio of recombinant CrmA to FLICE would be sufficient to block FLICE-induced apoptosis. As shown in Fig. 3B, this ratio completely abrogated the ability of FLICE to cleave caspase zymogens.


Fig. 3. Inhibition of FLICE-induced apoptosis by recombinant CrmA. A, HeLa nuclei were incubated with naive extract and recombinant FLICE for 2 h at 30 °C (lane 1). Tetrapeptide inhibitors Ac-DEVD-CHO (200 nM) (lane 2), Ac-YVAD-CHO (200 nM) (lane 3), or decreasing concentrations of recombinant CrmA (lanes 4-6) were added to naive extract prior to incubation with FLICE. Fragmentation of DNA was analyzed by agarose gel electrophoresis. B, radiotracer analysis of the activation of Tx, ICH1, LAP3, LAP6, FLICE2, FLICE, Yama, and Mch2 pro-enzymes (lanes 1, 4, 7, and 10) by FLICE in the presence of naive extract (lanes 2, 5, 8, and 11) and recombinant CrmA (lanes 3, 6, 9, and 12). C, interaction of recombinant FLICE with 35S-labeled CrmA. FLICE and CrmA (lane 2) or inactive FLICE with CrmA (lane 1) were incubated and immunoprecipitated with FLICE antiserum. The presence of coprecipitating CrmA was confirmed by SDS-PAGE and autoradiography (lanes 3 and 4). D, in vivo interaction of FLICE and CrmA. 293 cells were transfected with HA epitope-tagged FLICE (lanes 2 and 3) or CrmA (lanes 1 and 3), and the cell lysate was immunoprecipitated with HA-tag antibody. The immunoprecipitate was analyzed for the presence of CrmA by immunoblotting (lanes 4-6).
[View Larger Version of this Image (50K GIF file)]


To address whether FLICE and CrmA formed a physical complex, FLICE or catalytically inactive FLICE (obtained by prior incubation with Ac-DEVD-CHO) was directly incubated with 35S-labeled CrmA. The putative complex was precipitated using a FLICE antibody, and associating CrmA was detected by autoradiography. As shown in Fig. 3C, only the enzymatically active form of FLICE formed a complex with CrmA. The observed reduction in size of CrmA in the presence of FLICE is explained by the observation that denaturation of serpin-protease complexes results in cleavage of the serpin in the reactive site loop, leading to a corresponding decrease in molecular mass (19, 43). In vivo complex formation was demonstrated by transfecting epitope-tagged FLICE and CrmA expression constructs into 293 cells. Total cell lysates were assessed for CrmA expression by immunoblotting prior to immunoprecipitation (INPUT in Fig. 3D). CrmA was observed to be present in three forms with the 38-kDa band representing intact CrmA. The 32-kDa form presumably evolved upon cleavage within the reactive site loop on denaturation of the serpin-protease (CrmA-FLICE) complex. Nonspecific proteolysis within the cell lysate was likely responsible for the 26-kDa form. Regardless, upon FLICE immunoprecipitation, the 32-kDa form of CrmA was found to coprecipitate confirming the ability of the two molecules to form a complex in vivo. Taken together, the data presented are consistent with FLICE being the most apical member of the protease death cascade and a likely target for the cell death inhibitor CrmA.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   Recipient of a Human Frontier Science Program Organization (HFSPO) fellowship.
par    To whom correspondence should be addressed: Dept. of Pathology, the University of Michigan Medical School, 1301 Catherine St., Box 0602, Ann Arbor, MI 48109. Tel.: 313-647-2921; Fax: 313-764-4308; E-mail: vmdixit{at}umich.edu.
1    The abbreviations used are: caspase, cysteine aspartic acid specific protease; IL-1beta , interleukin-1beta ; ICE, interleukin-1beta converting enzyme; TNF, tumor necrosis factor; TNFR-1, tumor necrosis factor receptor 1; CrmA, cytokine response modifier A; LPS, lipopolysaccharide; PARP, poly(ADP-ribose) polymerase; serpin, serine protease inhibitor; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid.
2    C. Vincenz and V. M. Dixit, submitted for publication.

Acknowledgments

We thank Dr. Guy G. Poirier for anti-PARP antibody (C-2-10) and Dr. Brian Burke for anti-lamin A antibody. We wish to thank Arul Chinnaiyan, Hangjun Duan, Justin McCarthy, Kim Orth, and Karen O'Rourke for helpful discussions and encouragement. We are grateful to Ian Jones for his expertise in preparing the figures.


REFERENCES

  1. Raff, M. C. (1992) Nature 356, 397-400 [CrossRef][Medline] [Order article via Infotrieve]
  2. Steller, H. (1995) Science 267, 1445-1449 [Medline] [Order article via Infotrieve]
  3. Chinnaiyan, A. M., and Dixit, V. M. (1996) Curr. Biol. 6, 555-562 [Medline] [Order article via Infotrieve]
  4. Yuan, J., Shaham, S., Ledoux, S., Ellis, H. M., and Horvitz, H. R. (1993) Cell 75, 641-652 [Medline] [Order article via Infotrieve]
  5. Kumar, S., Kinoshita, M., Noda, M., Copeland, N. G., and Jenkins, N. A. (1994) Genes Dev. 8, 1613-1626 [Abstract]
  6. Wang, L., Miura, M., Bergeron, L., Zhu, H., and Yuan, J. (1994) Cell 78, 739-750 [Medline] [Order article via Infotrieve]
  7. Fernandes-Alnemri, T., Litwack, G., and Alnemri, E. S. (1994) J. Biol. Chem. 269, 30761-30764 [Abstract/Free Full Text]
  8. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T.-T., Yu, V. L., and Miller, D. K. (1995) Nature 376, 37-43 [CrossRef][Medline] [Order article via Infotrieve]
  9. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. (1995) Cell 81, 801-809 [Medline] [Order article via Infotrieve]
  10. Faucheu, C., Diu, A., Chan, A. W., Blanchet, A. M., Miossec, C., Herve, F., Collard-Dutilleul, V., Gu, Y., Aldape, R. A., Lippke, J. A., Rocher, C., Su, M. S. S., Livingston, D. T., Hercend, T., and Lalanne, J. L. (1995) EMBO J. 14, 1914-1922 [Abstract]
  11. Kamens, J., Paskind, M., Hugunin, M., Talanian, R. V., Allen, H., Banach, D., Bump, N., Hackett, M., Johnston, C. G., Li, P., Mankovich, J. A., Terranova, M., and Ghayur, T. (1995) J. Biol. Chem. 270, 15250-15256 [Abstract/Free Full Text]
  12. Munday, N. A., Vaillancourt, J. P., Ali, A., Casano, F. J., Miller, D. K., Molineaux, S. M., Yamin, T. T., Yu, V. L., and Nicholson, D. W. (1995) J. Biol. Chem. 270, 15870-15876 [Abstract/Free Full Text]
  13. Fernandes-Alnemri, T., Litwack, G., and Alnemri, E. S. (1995) Cancer Res. 55, 2737-2742 [Abstract]
  14. Duan, H., Chinnaiyan, A. M., Hudson, P. L., Wing, J. P., He, W., and Dixit, V. M. (1996) J. Biol. Chem. 271, 1621-1625 [Abstract/Free Full Text]
  15. Fernandes-Alnemri, T., Takahashi, A., Armstrong, R., Krebs, J., Fritz, L., Tomaselli, K. J., Wang, L., Yu, Z., Croce, C. M., Salvesen, G., Earnshaw, W. C., Litwack, G., and Alnemri, E. S. (1995) Cancer Res. 55, 6045-6052 [Abstract]
  16. Lippke, J. A., Gu, Y., Sarnecki, C., Caron, P. R., and Su, M. S.-S. (1996) J. Biol. Chem. 271, 1825-1828 [Abstract/Free Full Text]
  17. Duan, H., Orth, K., Chinnaiyan, A., Poirier, G., Froelich, C. J., He, W.-W., and Dixit, V. M. (1996) J. Biol. Chem. 271, 16720-16724 [Abstract/Free Full Text]
  18. Fernandes-Alnemri, T., Armstrong, R. C., Kreb, J., Srinivasula, S. M., Wang, L., Bullrich, F., Fritz, L. C., Trapani, J. A., Tomaselli, K. J., Litwack, G., and Alnemri, E. S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7464-7469 [Abstract/Free Full Text]
  19. Potempa, J., Korzus, E., and Travis, J. (1994) J. Biol. Chem. 269, 15957-15960 [Free Full Text]
  20. Wang, S., Miura, M., Jung, Y., Zhu, H., Gagliardini, V., Shi, L., Greenberg, A. H., and Yuan, J. (1996) J. Biol. Chem. 271, 20580-20587 [Abstract/Free Full Text]
  21. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Scaffidi, C., Bretz, J. D., Zhang, M., Ni, J., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) Cell 85, 817-827 [Medline] [Order article via Infotrieve]
  22. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. (1996) Cell 85, 803-815 [Medline] [Order article via Infotrieve]
  23. Chinnaiyan, A. M., Orth, K., O'Rourke, K., Duan, H., Poirier, G. G., and Dixit, V. M. (1996) J. Biol. Chem. 271, 4573-4576 [Abstract/Free Full Text]
  24. Orth, K., Chinnaiyan, A. M., Garg, M., Froelich, C. J., and Dixit, V. (1996) J. Biol. Chem. 271, 16443-16446 [Abstract/Free Full Text]
  25. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. (1995) Cell 81, 505-512 [Medline] [Order article via Infotrieve]
  26. Boldin, M. P., Varfolomeev, E. E., Panver, I. L., Mett, J. H., Camonis, J. H., and Wallach, D. (1995) J. Biol. Chem. 270, 7795-7798 [Abstract/Free Full Text]
  27. Chinnaiyan, A. M., Tepper, C. G., Seldin, M. F., O'Rourke, K., Kischkel, F. C., Hellbardt, S., Krammer, P. H., Peter, M. E., and Dixit, V. D. (1996) J. Biol. Chem. 271, 4961-4965 [Abstract/Free Full Text]
  28. Enari, M., Hug, H., and Nagata, S. (1995) Nature 375, 78-81 [CrossRef][Medline] [Order article via Infotrieve]
  29. Los, M., Van de Craen, M., Penning, L. C., Schenk, H., Westendorp, M., Baeuerle, P. A., Droge, W., Krammer, P. H., Fiers, W., and Schulze-Osthoff, K. (1995) Nature 375, 81-83 [CrossRef][Medline] [Order article via Infotrieve]
  30. Tewari, M., and Dixit, V. M. (1995) J. Biol. Chem. 270, 3255-3260 [Abstract/Free Full Text]
  31. Martin, S. J., Newmeyer, D. D., Mathias, S., Farschon, D. M., Wang, H., Reed, J. C., and Green, D. R. (1995) EMBO J. 14, 5191-5200 [Abstract]
  32. Lazebnik, Y. A., Cole, S., Cooke, C. A., Nelson, W. G., and Earnshaw, W. C. (1993) J. Cell Biol. 123, 7-22 [Abstract]
  33. Orth, K., O'Rourke, K., Salvesen, G., and Dixit, V. (1996) J. Biol. Chem. 271, 20977-20980 [Abstract/Free Full Text]
  34. Schlegel, J., Peters, I., Orrenius, S., Miller, D. K., Thornberry, N. A., Yamin, T.-T., and Nicholson, D. W. (1996) J. Biol. Chem. 271, 1841-1844 [Abstract/Free Full Text]
  35. Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., Elliston, K. O., Ayala, J. M., Casano, F. J., Chin, J., Ding, G. J.-F., Egger, L. A., Gaffney, E. P., Limjuco, G., Palyha, O. C., Raju, S. M., Rolando, A. M., Salley, J. P., Yamin, T.-T., Lee, T. D., Shively, J. E., MacCross, M., Mumford, R. A., Schmidt, J. A., and Tocci, M. J. (1992) Nature 356, 768-774 [CrossRef][Medline] [Order article via Infotrieve]
  36. Hasegawa, J., Kamada, S., Kamiike, W., Shimizu, S., Imazu, T., Matsuda, H., and Tsujimoto, Y. (1996) Cancer Res. 56, 1713-1718 [Abstract]
  37. Slee, E. A., Zhu, H., Chow, S. C., MacFarlane, M., Nicholson, D. W., and Cohen, G. M. (1996) Biochem. J. 315, 21-24 [Medline] [Order article via Infotrieve]
  38. Enari, M., Talanian, R. V., Wong, W. W., and Nagata, S. (1996) Nature 380, 723-726 [CrossRef][Medline] [Order article via Infotrieve]
  39. Kuida, K., Lippke, J. A., Ku, G., Harding, M. W., Livingston, D. J., Su, M. S. S., and Flavell, R. A. (1995) Science 267, 2000-2002 [Medline] [Order article via Infotrieve]
  40. Darmon, A. J., and Bleackley, C. R. (1996) J. Biol. Chem. 271, 21699-21702 [Abstract/Free Full Text]
  41. Gagliardini, V., Fernandez, P. A., Lee, R. K. K., Hannes, C. A., Drexler, H. C. A., Rotello, R. J., Fishman, M. C., and Yuan, J. (1994) Science 263, 826-828 [Medline] [Order article via Infotrieve]
  42. Ray, C. A., Black, R. A., Kronheim, S. R., Greenstreet, T. A., Sleath, P. R., Salvesen, G. S., and Pickup, D. J. (1992) Cell 69, 597-604 [Medline] [Order article via Infotrieve]
  43. Travis, J., and Salvesen, G. S. (1983) Annu. Rev. Biochem. 52, 655-709 [CrossRef][Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.